Topographical Body Fat Distribution Links to Amino Acid and Lipid Metabolism in Healthy Non-Obese Women

Francois-Pierre J. Martin1,¤a, Ivan Montoliu2, Sebastiano Collino1,¤a, Max Scherer1,¤a, Philippe Guy1, Isabelle Tavazzi1, Anita Thorimbert1, Sofia Moco1,¤b, Megan P. Rothney3, David L. Ergun4, Maurice Beaumont5, Fiona Ginty4, Salah D. Qanadli6, Lucie Favre7, Vittorio Giusti7, Serge Rezzi1,¤a,¤b

1 Metabolomics and Biomarkers, Nestec Ltd., Nestle Research Center, Lausanne, Switzerland, 2 Applied Mathematics, Nestec Ltd., Nestle Research Center, Lausanne, Switzerland, 3 Diagnostics and Biomedical Technology Organization, GE Global Research Center, Niskayuna, New York, United States of America, 4 GE Healthcare, Madison, Wisconsin, United States of America, 5 Clinical Development Unit, Nestec Ltd., Nestle Research Center, Lausanne, Switzerland, 6 Cardiothoracic and Vascular Unit, Department of Radiology, University Hospital of Lausanne, Lausanne, Switzerland, 7 Service of Endocrinology, Diabetology and Metabolism, Department of Medicine, University Hospital of Lausanne, Lausanne, Switzerland

Abstract

Visceral adiposity is increasingly recognized as a key condition for the development of obesity related disorders, with the ratio between visceral adipose tissue (VAT) and subcutaneous adipose tissue (SAT) reported as the best correlate of cardiometabolic risk. In this study, using a cohort of 40 obese females (age: 25–45 y, BMI: 28–40 kg/m²) under healthy clinical conditions and monitored over a 2 weeks period we examined the relationships between different body composition parameters, estimates of visceral adiposity and blood/urine metabolic profiles. Metabonomics and lipidomics analysis of blood plasma and urine were employed in combination with in vivo quantitation of body composition and abdominal fat distribution using iDXA and computerized tomography. Of the various visceral fat estimates, VAT/SAT and VAT/total abdominal fat ratios exhibited significant associations with regio-specific body lean and fat composition. The integration of these visceral fat estimates with metabolic profiles of blood and urine described a distinct amino acid, diacyl and ether phospholipid phenotype in women with higher visceral fat. Metabolites important in predicting visceral fat adiposity as assessed by Random forest analysis highlighted 7 most robust markers, including tyrosine, glutamine, PC-O 44:6, PC-O 44:4, PC-O 42:4, PC-O 40:4, and PC-O 40:3 lipid species. Unexpectedly, the visceral fat associated inflammatory profiles were shown to be highly influenced by inter-days and between-subject variations. Nevertheless, the visceral fat associated amino acid and lipid signature is proposed to be further validated for future patient stratification and cardiometabolic health diagnostics.

Citation: Martin F-PJ, Montoliu I, Collino S, Scheer M, Guy P, et al. (2013) Topographical Body Fat Distribution Links to Amino Acid and Lipid Metabolism in Healthy Non-Obese Women. PLoS ONE 8(9): e73445. doi:10.1371/journal.pone.0073445

Editor: Antonio Moschetta, University of Bari & Consorizio Mario Negri Sud, Italy

Received March 21, 2013; Accepted July 23, 2013; Published September 11, 2013

Copyright: © 2013 Martin et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: The authors have no support or funding to report.

Competing Interests: Authors FPM, SC, MS, SM, PG, IT, AT, SR are employees of Nestlé Institute of Health Science SA. Authors IM, MB are employees of Nestec S.A. Authors MPR, DLE, FG are employees of GE. This does not alter the authors’ adherence to all the PLOS ONE policies on sharing data and materials.

* E-mail: francois-pierre.martin@rd.nestle.com (FPJM); serge.rezzi@rd.nestle.com (SR)

¤a Current address: Molecular Biomarkers, Nestlé Institute of Health Sciences SA, Lausanne, Switzerland

¤b Current address: Natural Bioactives and Screening, Nestlé Institute of Health Sciences SA, Lausanne, Switzerland

Introduction

Overweight and obesity pandemic has made the discovery of their associated genome and metabolome one of the greatest public health challenges [1,2]. Obesity, in particular visceral adiposity, associates with inflammation and insulin resistance which ultimately link to risks of type 2 diabetes and cardiometabolic disorders. The mechanisms leading to obesity related diseases (ORD) remain yet undefined but may involve platelet and vascular impairments [3,4]. Moreover, visceral adiposity, also named central adiposity or obesity, is increasingly recognized as a key condition for the development of ORD [5–10].

The etiology and individual predisposition to visceral adiposity remain unclear. Over the last decades, both genetic and environmental promoters were investigated [11,12], including genes and transcription factors associated with fat storage and obesity [12–16], genetic inheritability [17] and gut microbiota influence [18]. Nevertheless, similar obesogenic and diabetogenic conditions do not necessarily lead to a universal response to adiposity-associated cardiometabolic risks [19,20]. Indeed, individuals with normal weight (body mass index, BMI<25) can express cardiometabolic abnormalities [19] putatively due to differences in body composition with a key role of sub-cutaneous versus visceral fat distribution.

From a diagnostic view, various indexes of visceral adiposity, combining anthropometric measures were proposed, including waist to hip ratio, (e.g. >0.9 for men and >0.85 for women) [21]. However, anthropometric-based stratification is prone to measurement errors. They also show limitations when applied across different populations (children versus adults) and ethnicities as universal health standards cutoffs. Moreover, these tools are insensitive to discerning the different sub-conditions of visceral adiposity and their associated metabolic risk factors. Visceral adiposity includes indeed a complex topographical fat deposition,
namely mesenteric and epicardial adipose tissues, and peripheric depots around organs like stomach, liver and kidneys, which associate with metabolic homeostatic loss [22]. The complex visceral fat compartment exhibits, beyond its role in dietary fat storage, signaling metabolic functions that interplay with endocrine and immune systems [12]. Modern imaging technologies based on magnetic resonance (MRI) and computed tomography (CT) can generate accurate region-specific quantification of visceral fat depots. Nevertheless, it is unlikely that these imaging platforms can become universal tools for population screening and monitoring due to cost and access limitations.

In such a context, the identification of minimally-invasive, fast and reliable biomarkers to be used for effective and individual therapeutic solutions for visceral adiposity management and monitoring has become a key milestone to address the burden of ORD with cost effective diagnostics at epidemiological level. The development of such biomarkers may benefit from metabolomics, which is well suited to delineate metabolic phenotype, encapsulating the influence of various environment, drugs, dietary, lifestyle, genetics, and microbiome factors [23–25]. Recent applications have demonstrated the feasibility of associating specific metabolite profiles to body fat distribution [26,27], and it is envisioned that metabolomics could deliver direct or indirect metabolic information that may generate new mechanistic knowledge of complex physiological processes.

We sought to identify visceral adiposity specific metabolic signature using a combination of holistic nuclear magnetic resonance (NMR) and targeted quantitative mass spectrometry (MS) analysis of urine and plasma from a well clinically characterized cohort of 40 healthy obese women. Subject characterization was based on clinical chemistry and body imaging including visceral adipose tissue (VAT) and subcutaneous adipose tissue (SAT) quantitation using gold standard CT completed with whole body Dual energy X-ray Absorptiometry (DXA) [28] scans. The VAT/SAT and VAT/total abdominal fat ratios, considered as cardiometabolic health indicators, were calculated to probe for metabolic-phenotype correlations [29]. In the present study, we assess how topography of visceral adiposity links to body composition parameters and metabolic status of healthy obese women.

**Materials and Methods**

**Ethics Statement**

This work was approved by the Ethical Committee of Lausanne University School Medicine (Lausanne, Switzerland). All participants gave written informed consent in French or in English as described in the consent procedure of the study protocol approved by the Ethics committee. The clinical study is registered at ClinicalTrials.gov with the identifier NCT01726647.

**Participants and Experimental Design**

The observational study was conducted on 40 healthy obese Caucasian women at the out-patient obesity clinic of the University Hospital of Lausanne (CHUV), Switzerland. The participants had a BMI between 28 and 40, aged between 25 and 45 years old, showed no metabolic disease traits, and gave written informed consent. Additional exclusion criteria were diabetes, pregnancy, antibiotic therapy within 1 month prior to the beginning of the study, any therapy (contraception apart) within the run-in period of one week before the visit day, and eating disorders. In the current cohort no subjects suffered from hypertension, glucose intolerance, polycystic ovary syndrome, thyroid dysfunction and adrenal disorders. Subjects having recently undergone a weight loss of more than 3 kilos during the last 3 months were also excluded. During the conduction of the study, participants were asked to limit consumption of special foods (spices, supplements, etc.) for one week before the first visit day and to record their daily food intake. Fourteen subjects out of the 40 were taking contraception, and the subjects followed a randomized distribution across the spectrum of visceral fat adiposity. All the subjects showed normal menstrual cycle and took part in the study during the follicular phase of their menstrual cycle to minimize the confounding effects related to the hormonal changes. At a baseline (V0), subjects underwent a standard medical visit, where overnight fasting blood plasma samples were collected. One week later (V1), body composition was measured using CT (at CHUV) and iDXA (at the metabolic unit, Nestlé Research Center, Lausanne, Switzerland). Twenty-four-hours urine samples were collected, resting energy expenditure was measured by indirect calorimetry and a standard Oral Glucose Tolerance Test (OGTT, 75 g glucose) was conducted at V1. Glucose and insulin concentrations were measured at −15 min (t₀), +30 min (t₃₀), +60 min (t₆₀), +90 min (t₉₀), +120 min (t₁₂₀) after glucose intake. One week later (V2), the subjects were asked to consume a standardized lunch and dinner to smooth inter-individual differences due to differences in diets. At this time point, overnight fasting plasma and 24-hours urine samples were collected, and fasting plasma samples again on the next day (V3).

**Anthropometric Measurements**

Body weight was measured with a Detecto® scale with a precision of 0.2 kg; height was measured with a stadiometer with a precision of 0.5 cm. Body mass index (BMI) was calculated as weight/height squared (kg/m²). Waist and hip circumferences were taken respectively at the smallest standing horizontal circumference between the ribs and the iliac crest and in a horizontal plane around the maximum circumference of the buttocks, using a TEC anthropometric tape (Rollfix, Hoechstmass, Germany). The measurement was made on a GE Lunar iDXA system (software version: enCORE version 12.10.113) with scan mode automatically determined by the device and used the previously reported procedure [28]. For the DXA measurement, all subjects were wearing a hospital gown and had all metal artefacts removed. The iDXA unit was calibrated daily using the GE Lunar calibration phantom. A trained operator performed all scans following the operator’s manual for patient positioning and data acquisition. During the one-hour appointment, total body scans of each subject were performed twice with repositioning between scans. Scans were analyzed with the enCORE software (version 14.00.207). The ROIs were automatically determined by the enCORE software (Auto ROI) for total body, arms, legs, trunk, android, and gynoid regions. An experienced DXA operator also verified and, when indicated, repositioned the ROI placements (Expert ROI). In addition to iDXA scan, waist and hip measurements were performed.

**Body Composition Assessment and Energy Expenditure Assessments**

Full body scan was performed to determine both abdominal fat distribution and total body composition. Total body scans were made on a GE Lunar iDXA system (software version: enCORE version 12.10.113) with scan mode automatically determined by the device and used the previously reported procedure [28]. For the DXA measurement, all subjects were wearing a hospital gown and had all metal artefacts removed. The iDXA unit was calibrated daily using the GE Lunar calibration phantom. A trained operator performed all scans following the operator’s manual for patient positioning and data acquisition. During the one-hour appointment, total body scans of each subject were performed twice with repositioning between scans. Scans were analyzed with the enCORE software (version 14.00.207). The ROIs were automatically determined by the enCORE software (Auto ROI) for total body, arms, legs, trunk, android, and gynoid regions. An experienced DXA operator also verified and, when indicated, repositioned the ROI placements (Expert ROI). In addition to iDXA scan, waist and hip measurements were performed.
The CT scan measures of the abdominal region, for the quantification of intra-peritoneal and sub-cutaneous fat, were performed on 64 multi-detector CT scanner (VCT Lightspeed, GE Medical Systems, Milwaukee, USA). Subjects lied in the supine position with their arms above their head and legs elevated with a cushion. A single scan (10 mm) of the abdomen is acquired at the level of L4–L5 vertebrae and analyzed for a cross-sectional area of adipose tissue, expressed in square centimeters. The following acquisition parameters were used: 120 Kv, 100–200 mA with z-axis dose modulation and a field of view 500 mm. Axial transverse images of 5 mm slice thickness are reconstructed using a standard kernel. The quantification process uses a semi interactive commercially available algorithm for segmentation of subcutaneous and intra-abdominal fat on the Advantage Window workstation (GE Medical Systems). Resting metabolic rate was measured by using open-circuit indirect calorimetry, with a Delmatrak II (Datex Instruments).

Blood Pressure and Clinical Chemistry

Blood pressure was measured in the lying position using a digital pressure monitor (HEM-907, Omron). Mean arterial blood pressure (MAP) was also calculated from systolic (SYS) and diastolic (DIA) arterial blood pressure: MAP = 1/3 SYS +2/3 DIA. Blood samples were collected in the morning after an overnight fast. Glucose (Ecoline 100 Merck, KgaA, Darmstadt, Germany), total cholesterol (Roche CHOD-PAP, Roche Molecular Biochemicals Systems, GmbH, Mannheim, Germany), high-density lipoprotein cholesterol (HDL-C plus, second generation, Roche Diagnostic GmbH, Mannheim, Germany) and triglycerides (TG GPO-PAP, Roche Diagnostic) were measured using an automatic Hitachi 917 Roche apparatus. Low-density lipoprotein cholesterol was then calculated by the Friedwald’s formula. Plasma insulin was assayed by specific radioimmunoassay (Aldatis Insulin, code 10624, Casalecchio di Reno, BO, Italy). Urea, creatinine, sodium and potassium concentrations, ALAT, ASAT, γGT, were measured by SSCC (Société Suisse de Chimie Clinique) 37°C method with kit Roche and kit BioMérieux with automatic Hitachi 917 Roche, according to routine analytic methods. Intrassay precision error (CV) for these measurements was 1.0–3.1%. All biochemical analyses were carried out by certified laboratories (ISO/CEI 17025); they were run in duplicate or triplicate samples, after having been previously tested in a healthy population. Insulin resistance status was assessed as homeostasis model assessment of insulin resistance (HOMA-IR); insulin (μU/mL) x glucose (mmol/L)/22.5. Finally, free fatty acids were analyzed by WAKO NEFA-HR (300 μL plasma, EDTA) using Siemens XPAND DIMENSION (WA2 434–91795, WA2 436–91995, USA).

Metabonomics Analysis

Targeted LC-MS/MS metabonomic approach using the Biocrates Life Sciences AbsoluteID QT kit was applied to plasma samples as previously published [30]. Briefly, well plate preparation and sample application and extraction were carried out according to the manufacturer’s instructions. A final volume of 10 μL of plasma was loaded onto the provided 96-well plate. Liquid chromatography was realized on a Dionex UltiMate 3000 ultra high pressure liquid chromatography (UHPLC) system (Dionex AG, Olten, Switzerland) coupled to a 3200 Q TRAP mass spectrometer (AB Sciex; Foster City, CA, USA) fitted with a TurboV ion source operating in electrospray ionization (ESI) mode. Sample extracts (20 μL) were injected twice (in positive and negative ESI modes) via direct infusion using a gradient flow rate of 0–2.4 min: 30 μL/min, 2.4–2.8 min: 200 μL/min, 2.9–3 min: 30 μL/min. MS source parameters were set at: desolvation temperature (TEM): 200°C, high voltage: −4500 V (ESI –), 5500 V (ESI +), curtain (CUR) and nebuliser (GS1 and GS2) gases: nitrogen; 20, 40, and 50 psi; respectively, nitrogen collision gas pressure: 5 mTorr. MS/MS acquisition was realised in scheduled reaction monitoring (SRM) mode with optimised declustering potential values for the 163 metabolites screened in the assay. Raw data files (Analyst software, version 1.5.1; AB Sciex, Foster City, CA, USA) were imported into the provided analysis software MetIQ to calculate metabolite concentrations. List of all detectable metabolites is available from Biocrates Life Sciences, Austria (http://biocrates.com). See Text S1 for more details. Samples were also subjected to analysis for inflammation markers quantification by UPLC-ESI-MS/MS using isotope dilution technique. See Text S2 for more details.

Heparinized blood plasma samples (400 μL) were introduced into 5 mm NMR tubes with 200 μL of deuterated phosphate buffer solution (KH₂PO₄ with a final concentration of 0.2 M). Deuterium was employed as locking substance. Twenty-four-hours urine samples (400 μL) were introduced into 5 mm NMR tubes with 200 μL of deuterated phosphate buffer solution (KH₂PO₄ with a final concentration of 0.2 M, and containing 1 mM of sodium 3-(trimethylsilyl)-[2,2,3,3-2H₄]-1-propionate (TSP). Metabolic profiles were measured on a Bruker Avance III 600 MHz spectrometer equipped with an inverse 5 mm cryogenic probe at 300 K (Bruker Biospin, Rheinstetten, Germany). See Text S3 for more details.

Chromometrics

Due to the non-normal distribution of the visceral adiposity, the following parameters were employed for the subsequent metabonomics analysis: log-transform value of the visceral fat content, of the intraperitoneal/subcutaneous fat ratio (ratio 1), or of the intraperitoneal/abdominal fat ratio (ratio 2). The plasma and urine NMR spectra were converted into 22 K data points over the range of 6.2–10.0 ppm using an in-house developed MATLAB routine excluding the water residue signal between δ4.68–5.10 ppm. Chemical shift intensities were normalized to the sum of all intensities within the specified range prior to chromometric analysis for urine and plasma samples. In addition, 24-hours urine spectral data were also normalized to creatinine values quantified in parallel using an adapted Jaffé method.

Chromometric analysis was performed using the software package SIMCA-P+ (version 12.0, Umetrics AB, Umeå, Sweden) and in-house developed MATLAB (The MathWorks Inc., Natick, MA, USA) routines. In order to detect the presence of similarities between metabolic profiles, Principal Component Analysis (PCA) [31], Projection to Latent Structure (PLS) [32], and the Orthogonal Projection to Latent Structures (O-PLS) [33] were used. Analyses were conducted to investigate relationships between body composition, OGTT response and metabolic profiles. Seven-fold cross validation was used to assess the validity of the model [34]. The classification accuracy of the O-PLS-DA model was established from the predicted samples in the 7-fold cross-validation cycle. The modeling was also tested for assessing inter-days metabolic variations, by considering each visit separately.

In addition, targeted MS data were analyzed by Random Forests (RF™) using the package ‘randomForest’ [35]. In particular, the selection of the most robust markers required additional multivariate data analyses using RF™ (with 500 trees, and a random variable sampling at tree split of 5) and the implemented variable importance features in RF™ (mean
Table 1. Descriptive statistics of subjects stratified according to intraperitoneal/abdominal fat ratio.

| Factor       | Q1             | Q2             | Q3             | Q4             | Mann-Whitney p value (Q1/Q4) |
|--------------|----------------|----------------|----------------|----------------|-------------------------------|
| Log10 Ratio2 | -0.7±0.05      | -0.6±0.02      | -0.52±0.02     | -0.40±0.06     | <0.0001                       |
| IPVF, mL     | 3065.1±695.5   | 4223±837.6     | 5111.2±1036.3  | 5407±1564.6    | 0.0002                         |
| HOMA-IR      | 4.24±2.02      | 4.95±1.49      | 6.06±1.87      | 6.12±1.23      | 0.011                          |
| Insulin, (μU/mL) | 18.6±9.21      | 22.12±6.32     | 24.36±7.22     | 25.44±4.62     | 0.014                          |
| Glucose, mmol/L | 4.95±0.35      | 5.17±0.52      | 5.41±0.49      | 5.37±0.5       | 0.057                          |
| TG, mmol/L   | 1.04±0.43      | 2.25±2.1       | 1.28±0.45      | 1.52±0.57      | 0.093                          |
| ALAT/ASAT ratio | 0.86±0.25      | 0.91±0.21      | 0.99±0.3       | 1.08±0.34      | 0.120                          |
| Age, years   | 33.9±4.89      | 32.8±3.58      | 38±4.42        | 37.6±5.82      | 0.138                          |
| ALAT, U/L    | 18.4±6.11      | 19.2±5.07      | 23.5±8.34      | 27.1±13.28     | 0.139                          |
| HDL, mmol/L  | 1.54±0.43      | 1.32±0.29      | 1.38±0.25      | 1.32±0.24      | 0.181                          |
| GGT, U/L     | 20±11.86       | 17.5±6.88      | 21.1±4.84      | 25.44±11.26    | 0.191                          |
| Creatinine, mmol/L | 65.6±9.45      | 65.2±11.2      | 64.78±9.28    | 70.3±6.53      | 0.256                          |
| HDL/Chol ratio | 3.77±1.07      | 4.42±1.22      | 3.99±0.97      | 4.24±0.95      | 0.289                          |
| Na, mmol/L   | 140.4±1.35     | 140.8±1.32     | 141.5±1.58     | 139.9±1.1      | 0.328                          |
| Waist/Hip ratio | 0.8±0.07      | 0.81±0.06      | 0.85±0.07      | 0.84±0.09      | 0.351                          |
| Urates, μmol/L | 275.2±41.93    | 263.22±71.45   | 303.4±75.28    | 285±31.7      | 0.352                          |
| Calorimetry, kcal/24 h | 1357±191.78    | 1434±142.61    | 1469±152.49    | 1433±210.82    | 0.363                          |
| ASAT, U/L    | 21.4±3.24      | 21.4±4.48      | 24±6.94        | 24.5±6.7      | 0.401                          |
| Waist, cm    | 97.28±8.28     | 103.39±6.7     | 108.72±11.71   | 104.73±13.84   | 0.458                          |
| Hip, cm      | 122±5.47       | 128±7.48       | 127.34±6.29    | 122.28±9.65   | 0.564                          |
| NEFAs, μmol/L | 544.5±201.51   | 580±301.38     | 596.2±185.79   | 585.1±188.62   | 0.664                          |
| K, mmol/L    | 4.05±0.18      | 4.1±0.18       | 3.99±0.25      | 4.04±0.18     | 0.876                          |
| MAP, mmHg    | 57.8±18.6      | 71.1±19.75     | 62.4±20.97     | 57.8±14.15     | 0.879                          |
| Cholesterol, mmol/L | 5.52±1.01      | 5.58±0.85      | 5.31±0.68      | 5.48±0.97      | 0.909                          |
| BMI, kg/m²   | 34.01±3.27     | 36.34±3.62     | 37±2.95        | 34.59±4.42     | 0.939                          |
| LDL, mmol/L  | 3.5±0.97       | 3.56±0.88      | 3.34±0.61      | 3.47±0.79      | 1                              |

Key: Q: data for population quartile i according to intraperitoneal/abdominal fat ratio. BMI = body mass index, HDL-C = high density lipoprotein cholesterol, homeostasis model assessment of insulin resistance = HOMA-IR, LDL-C = low density lipoprotein cholesterol, TG = triglycerides, MAP = mean arterial blood pressure, ALAT = alanine aminotransferase, ASAT = aspartate aminotransferase, GGT = gamma-glutamyl transpeptidase, NEFAs = non esterified fatty acids. Data are reported as mean values ± SD.
doi:10.1371/journal.pone.0073445.t001
relationships between Log10 ratio 1 and the other parameters were further assessed using a OPLS multivariate model (Figure S4).

Visceral Adiposity Links to Different Metabolic Response to Oral Glucose Tolerance Test

Overall glucose and insulin response to OGTT correlated significantly with visceral adiposity as observed by linear regression with OGTT glucose and insulin AUC (Figure S3). When comparing subjects stratified according to VAT content defined quartiles, glucose-induced insulin secretion gradually increased between Q1 and Q4. However, significant blood glucose variations were only observed within the first 60 minutes post-glucose absorption across the VAT quartiles (Table 2, similar response was observed for different Log10 ratios).

Plasma Metabolic Profiles Revealed a Lipid and Amino Acid Signature Associated with Visceral Adiposity

In order to identify phenotypic signatures of visceral fat deposition, plasma samples were analysed using 1H-NMR and targeted LC-MS/MS metabonomic approach. Analyses were conducted on the fasting plasma samples collected at V0 and V2. OPLS analysis of 1H-NMR samples collected at V0 and V2

Figure 1. Statistically significant Spearman correlation map between CT scan and DXA body composition parameters (95% confidence interval). IPVF and Log10 IPVF correlated similarly to fat body composition parameters. Log10 IPVF showed a strong association with android/gynoid fat ratio (r = 0.48, p = 0.0015), Log10 VAT/SAT (r = 0.72, p<0.001) and Log10 VAT/total abdominal fat (r = 0.71, p<0.001), subcutaneous fat (r = 0.58, p<0.001), and some dependencies with lean mass parameters. Log10 values of VAT/SAT and VAT/total abdominal fat ratios were poorly correlated with most body composition parameters, except for arms lean mass (r = 0.43, p = 0.0056; r = 0.42, p = 0.0070), whilst VAT/SAT correlated with subcutaneous fat (r = 0.58, p = 0.0489), and android/gynoid fat ratio (r = 0.48, p = 0.0453). NB: Blue denotes negative correlation, orange denotes positive correlation, and black denotes no correlation.

doi:10.1371/journal.pone.0073445.g001
showed some subtle but significant associations between blood plasma lipids and visceral fat deposition ($R^2X: 0.68; R^2Y: 0.506; Q^2Y: 0.167$), further confirmed by random forest analysis (Figure S6). These results suggested plasma lipid remodelling marked by changes in glycerophospholipids and fatty acid saturation patterns.

Targeted MS metabonomics provided quantitative measures of 163 metabolites, including amino acids, sugars, acyl-carnitines, sphingolipids, and glycerophospholipids in plasma samples. A metabolic signature of visceral fat adiposity was determined using an OPLS analysis across the 40 individual subjects ($R^2X: 0.29; R^2Y: 0.68; Q^2Y: 0.32$). The model was then tested for assessing inter-days metabolic variations, by considering each visit separately and by modelling potential inter-days metabolic differences (data not shown). No statistically significant differences were observed in the blood plasma metabolic profile between V0 and V2 (data not shown). Furthermore, the most robust metabolic signatures of visceral fat status using either value of the intraperitoneal fat volume, ratio 1 and ratio 2, were selected by Random Forests analysis. Using this methodology, metabolite importance and robustness in predicting visceral fat adiposity were assessed using metabolic data collected at V0 and V2 (Figure 3). A signature of specific amino acids, diacyl phospholipids and ether lipid species was identified and shown to be preserved significantly between days (Figure 3). Ultimately, 26 metabolites were retained...
Table 2. Insulin and glucose response to oral glucose tolerance test according to intraperitoneal/abdominal fat ratio.

| Time variations | Delta t30–t0 | Delta t60–t0 | Delta t90–t0 | Delta t120–t0 |
|----------------|-------------|-------------|-------------|--------------|
| Insulin concentrations (mU/mL) | 74.69±31.76 | 85.94±49.76 | 75.25±41.38 | 38.93±32.32 |
| Q1 | 77.93±33.43 | 97.04±41.48 | 62.87±34.48 | 54.27±31.97 |
| Q2 | 79.25±52.36 | 68.07±42.78 | 91.01±55.36 | 66.61±52.39 |
| Q3 | 108.80±49.86 | 114.76±64.45 | 108.73±49.17 | 70.92±29.56 |
| t-test p values (Q1 vs. Q4) | 0.085 | 0.278 | 0.117 | 0.033 |
| Glucose concentrations (mmol/L) | | | | |
| Q1 | 1.63±0.71 | 1.30±1.01 | 0.74±0.086 | 0.01±1.86 |
| Q2 | 2.48±0.60 | 2.29±1.39 | 1.68±3.47 | 1.88±3.72 |
| Q3 | 3.03±1.42 | 2.81±1.59 | 1.79±1.60 | 1.16±1.28 |
| Q4 | 3.21±0.93 | 3.33±1.6 | 1.95±2.00 | 1.09±2.05 |
| t-test p values (Q1 vs. Q4) | 0.0005 | 0.0006 | 0.096 | 0.2355 |
| Estimates of beta cell function and insulin sensitivity OGTT Delta(Ins t30–t0)/(Gly t30–t0) | | | | |
| Q1 | 52.09±26.56 | | | |
| Q2 | 31.16±12.20 | | | |
| Q3 | 39.42±32.53 | | | |
| Q4 | 41.81±40.61 | | | |
| t-test p values (Q1 vs. Q4) | 0.511 | | | |

NB: Values are reported as mean values ± SD. Key: Q: data for population quartile i according to intraperitoneal/abdominal fat ratio.
doi:10.1371/journal.pone.0073445.t002

(Figure 3, Table 3, Table S3 and Table S4). Metabolite importance and robustness in predicting visceral fat adiposity as assessed by Random forest analysis using metabolic data collected at V0 and V2, highlighted 7 most robust markers, including tyrosine, glutamine, PC-O 44:6, PC-O 44:4, PC-O 42:4, PC-O 40:4, and PC-O 40:3.

To assess potential overlaps with insulin resistance, the predictive performance of the seven most promising markers was evaluated using two linear discriminant classification models based on both visceral fat and HOMA-IR stratification of the population. Model on visceral fat showed a sensitivity and specificity in cross-validation of 0.90, which was fairly different from the model on HOMA-IR (sensitivity (CV): 0.68). This loss of specificity for the HOMA-IR model was interpreted as a stronger association of the selected markers with visceral adiposity. Figure 4 displays metabolite variations in the study population stratified in four quartiles according to visceral fat adiposity (Log10 value of intraperitoneal fat).

Eicosanoid Profiling Suggests that the Relationship between Visceral Adiposity, Inflammation and Oxidative Stress is Affected by other Environmental Confounders

To investigate relationships between visceral fat deposition and low-grade inflammatory status, a targeted LC-MS/MS method was employed to measure plasma eicosanoid concentrations at V0 and V2. Here, Random Forests analysis on quantitative data displayed statistical relevant changes associated with the visceral adiposity (Table 3, Figure S7, Table S3 and Table S4).

Urine Metabolic Profiles Suggested a Different Energy and Microbial Metabolism in Subjects with High Visceral Adiposity

1H-NMR spectra of the 24 hours urine samples were normalized to creatinine concentration and were analyzed using supervised chemometric analysis to assess the occurrence of relationships with visceral adiposity. PLS analyses using 2 predictive components showed relationships between urine metabolic profile and visceral adiposity, at both timepoints, V1 or V2 (respective Q2Y values being 0.05, 0.217 and 0.54). OPLS analysis confirmed a statistically significant relationship at V2 (1 predictive and 2 orthogonal components, Q2Y value of 0.27). Visceral adiposity was correlated with changes in central energy metabolism (increased urinary excretion of 3-methyl-2-oxovaleric acid (direct catabolic product of isoleucine), N1-methyl-2-pyridone-5-carboxamide (2PY), N1-methyl-4-pyridone-3-carboxamide (4PY), fucose, pyruvate, pyrrolidinolamine and lactate), protein metabolism (increased pseudouridine, decreased taurine, and 3-methyl-histidine), and gut microbial activities (decreased 4-cresol sulfate). Since the subjects received a controlled dietary intake during V2, these results suggest a strong incident of visceral fat adiposity on individual nutritional response as noted here.

Integration of Visceral Adiposity, Clinical Parameters and Metabonomics Markers

A heat map based on the Spearman correlations on CT scan, main clinical parameters and selected discriminant metabolites measured in plasma and urine of the 40 human subjects was used to assess the relationships between the urine and plasma metabonomics readouts and key physiological endpoints. These correlations are shown in Figure 5 and Figure S8. Such an approach enabled the assessment of linear relationships between the parameters across the 40 subjects. In addition, for the 26 most influential metabolites, the VIP values generated from PLS regression against the visceral fat estimates are reported in Table S5, to further exemplify these relationships. In particular, we investigated the statistical relationships between selected metabolites, HOMA-IR, ALAT/ASAT ratio and visceral adiposity (Figure 5). The spearman correlation network between blood...
plasma metabolites showed a strong connection between the remodelling of ether lipid species and specific diacyl phospholipids, which seem quite independent of changes in eicosanoids and amino acids.

**Discussion**

Over the last decades, there was increasing awareness that prevalence of fat storage in the trunk/Android compartment over gynoid (i.e. mainly subcutaneous) region associates with increased insulin resistance and related cardiometabolic risk [36,37]. Assessments of visceral adiposity using VAT/SAT (ratio 1) and VAT/total abdominal fat (ratio 2) ratios were conducted in the present study, as they are known to better correlate to cardiometabolic health, outperforming associative power of single BMI and VAT [29]. In our cohort, IPVF, Log₁₀ IPVF and waist/hip ratio correlated similarly to several fat body composition parameters (total, trunk, arms, android and abdominal fat), concurring with literature [26,36,37]. VAT/SAT and VAT/total abdominal fat ratios were independent of these variables, and also related to android/gynoid fat ratio. Visceral adiposity expressed by log₁₀ values of IPVF, ratios 1 and 2 associated significantly with insulin (fasting insulin, HOMA-IR) and hepatic (ALAT/ASAT) metabolism unlike with other clinical parameters, including HDL, LDL, and TG, which is consistent with the healthy status of the enrolled subjects.

**Ether Lipid Metabolic Signature of Visceral Adiposity**

Highlights Potential Deregulations in Lipoprotein and Phospholipid Metabolic Pathways

A visceral fat signature of specific amino acids and ether phosphocholine lipid species was shown to be preserved significantly between days (Figure 3). Ether lipid species represent 18% of the total pool of phospholipids and are mainly composed by plasmalogens. Although little is known about their systemic metabolism, plasmalogens have been implicated in protection of cellular functions against oxidative damage [38], and their
Metabolic Signatures of Visceral Adiposity

Table 3. Metabolite variations across strains stratified according to intraperitoneal/abdominal fat ratio.

| Metabolites (concentration) | Q1    | Q2    | Q3    | Q4    | Mann-Whitney p value (Q1/Q4) |
|-----------------------------|-------|-------|-------|-------|-----------------------------|
| PC-O 42:4*, μmol/L          | 1.34±0.33 | 1.09±0.28 | 1.09±0.37 | 0.82±0.22 | 0.00298                   |
| PC-O 403*, μmol/L           | 1.41±0.27 | 1.46±0.38 | 1.27±0.3 | 0.86±0.42 | 0.00421                   |
| PC-O 446*, μmol/L           | 1.52±0.56 | 1.22±0.3 | 1.11±0.5 | 1.03±0.32 | 0.01013                   |
| PC-O 444*, μmol/L           | 0.8±0.3 | 0.67±0.24 | 0.63±0.19 | 0.51±0.18 | 0.01721                   |
| PC-O 404*, μmol/L           | 2.79±0.56 | 2.9±0.73 | 2.47±0.69 | 2.02±0.83 | 0.01784                   |
| Glutamine, μmol/L           | 615.56±107.95 | 748±193.49 | 792.1±260.61 | 714±94.03 | 0.02468                   |
| PC-O 363*, μmol/L           | 7.04±1.68 | 6.7±2.61 | 7.11±1.82 | 5.5±1.24 | 0.02792                   |
| 8-iso-PGF2α, ng/100 μL      | 0.008±0.011 | 0.004±0.001 | 0.003±0.002 | 0.003±0.001 | 0.0370                   |
| Phenylalanine, μmol/L       | 49.9±14.16 | 50.47±8.45 | 62.82±22.17 | 56.42±8.38 | 0.04113                   |
| PC-O 445*, μmol/L           | 2.29±0.74 | 2.03±0.55 | 1.9±0.74 | 1.71±0.7 | 0.04113                   |
| Leucine+Isoleucine, μmol/L  | 181.44±53.02 | 214.2±56.71 | 202.4±27.39 | 228.8±33.83 | 0.04536                   |
| Tyrosine, μmol/L            | 61.97±11.02 | 80.54±22.21 | 75.91±21.83 | 80.99±24.69 | 0.05347                   |
| PC-O 422*, μmol/L           | 0.66±0.23 | 0.56±0.14 | 0.53±0.16 | 0.45±0.18 | 0.05347                   |
| PC-O 406*, μmol/L           | 3.81±0.86 | 3.27±1.09 | 2.82±0.84 | 2.74±1.09 | 0.06525                   |
| PC-O 423*, μmol/L           | 0.89±0.2 | 0.92±0.14 | 0.9±0.27 | 0.63±0.26 | 0.06525                   |
| PC-O 362*, μmol/L           | 11.29±2.64 | 11.86±2.68 | 10.38±3.08 | 9.17±2.09 | 0.07865                   |
| PC-O 420, μmol/L            | 0.65±0.23 | 0.48±0.16 | 0.47±0.08 | 0.48±0.14 | 0.07889                   |
| Palmitoylcarnitine, μmol/L  | 0.07±0.02 | 0.07±0.03 | 0.07±0.03 | 0.1±0.04 | 0.12065                   |
| PC-O 300, μmol/L            | 4.43±1.48 | 5.17±2.35 | 5.75±1.98 | 5.57±1.76 | 0.1564                    |
| PC-O 443*, μmol/L           | 0.21±0.06 | 0.2±0.04 | 0.15±0.06 | 0.17±0.05 | 0.1564                    |
| PC-O 341*, μmol/L           | 9.94±2.22 | 9.78±3.84 | 8.48±2.15 | 8.53±0.99 | 0.17752                   |
| 15-HETE, ng/100 μL          | 0.08±0.05 | 0.17±0.29 | 0.1±0.13 | 0.1±0.18 | 0.18231                   |
| PC-O 342*, μmol/L           | 10.66±3.5 | 9.31±3.5 | 9.38±4.57 | 8.77±1.76 | 0.21102                   |
| LPC 24:0, μmol/L            | 0.36±0.25 | 0.51±0.24 | 0.52±0.36 | 0.46±0.31 | 0.21613                   |
| Ocytenoylcarnitine, μmol/L  | 0.04±0.02 | 0.05±0.02 | 0.05±0.04 | 0.05±0.02 | 0.25258                   |
| 9-HODE, ng/100 μL           | 0.10±0.02 | 0.12±0.05 | 0.11±0.02 | 0.12±0.04 | 0.25831                   |
| PC 34:4, μmol/L             | 1.3±0.46 | 1.53±1.14 | 1.41±0.52 | 1.55±0.75 | 0.31537                   |
| Caproylcarnitine, μmol/L    | 0.22±0.1 | 0.2±0.09 | 0.14±0.06 | 0.30±0.19 | 0.40018                   |
| PC-O 422, μmol/L            | 0.2±0.06 | 0.19±0.11 | 0.13±0.05 | 0.17±0.08 | 0.40018                   |
| 12-HETE, ng/100 μL          | 0.60±0.72 | 0.28±0.3 | 1.15±2.15 | 0.41±0.36 | 0.8421                    |
| AA, ng/100 μL               | 784.22±236.64 | 764.9±314.46 | 854.7±193.24 | 785.6±160.86 | 0.96823                   |

NB: Blood plasma metabolites highlighted by multivariate analyses are represented as mean values ± SD. Key: Q1: data for population quartile i according to intraperitoneal/abdominal fat ratio. 12-HETE, 12-hydroxy-eicosatetraenoic acid; 15-HETE, 15-hydroxy-eicosatetraenoic acid; 9-HODE, 9-Hydroxy-12,10-octadecadienoic acid; AA, arachidonic acid; LPC, Lysophosphatidylcholines; PC, Phosphatidylcholines; PC-O, 1-O-alkyl-2-aclylgerosphosphocholines; SM, Sphingomyelins; SM-OH, Hydroxy-Sphingomyelin.

*Assignment of PC-O species is made on the assumption that only even numbered carbon chains are present. A potential overlap between PC species containing odd-chain fatty acids and even-chained PC-O species cannot be excluded with low mass resolution.
doi:10.1371/journal.pone.0073445.t003

diminished levels have been reported in several diseases [39], e.g. diabetes mellitus, vascular diseases and obesity [40] or peroxisome biogenesis defects [41], all these conditions exhibiting a common feature as regards with oxidative stress. Furthermore, our work supports the association of polyunsaturated phospholipids species with visceral adiposity [40]. Using a correlation analysis, PC-O species reduced with increased visceral fat adiposity and positively correlated to HDL circulating levels, a feature previously reported for ageing-associated cardiometabolic disorders [42] and lipoprotein associated with visceral adiposity [26,43,44]. Indeed, lipoprotein fractions (VLDL, LDL, and HDL) were previously characterized by a specific ether lipid class and species pattern [39]. Our results confirm the involvement of PC-O species in glucose metabolism providing an additional pattern of PC-O species (PC-O 40:3, PC-O 40:4, PC-O 42:4, PC-O 44:3, and PC-O 44:6) newly associated with visceral adiposity. Further correlation analysis showed significant association between HOMA-IR and circulating levels of PC-O 44:4, PC-O 44:5, PC-O 44:6 and PC-O 42:4. Fuegel et al. reported a pattern of PC-O species (PC-O 34:3, PC-O 40:6, PC-O 42:5, PC-O 44:4, and PC-O 44:5) correlated with risk of T2D [45]. Taken together with literature data, our results suggest the occurrence of a subset of PC-O species (PC-O 40:3, PC-O 40:4, and PC-O 44:3) that would be specific to visceral adiposity. Additionally, we observe that PC-O 42:4, PC-O 44:4, PC-O 44:5 and PC-O 44:6 appear as constant feature of insulin resistance status or Type 2 pre-diabetic state.
Our results further supported by the recent study by Szymanska et al. [26], strongly suggest a remodelling of phospholipid species, which may result from a multi-factorial origin, including dietary factors, gut functional ecology, intestinal absorption, as well as Platelet-Activating Factor (PAF) metabolic pathways and phospholipase A2 activities [46,47], which are modulated by obesity and insulin resistance [3,48].

Evidence tends to support the notion that oxidative-stress-induced dysregulation of inflammation and adipokines may mediate the obesity-related metabolic derangement [49]. Here, high visceral fat subjects tend to display a different balanced network of lipid mediators, as noted by an alteration of the arachidonic metabolism. However, the greater inter-day variability in the dynamics of these pathways may suggest that the visceral-
associated influence is also dependent on lifestyle and dietary intakes. Previously reported studies displayed how enhanced lipid peroxidation and persistent platelet activation associate to visceral adiposity might be influenced by weight-loss program or simply by the type of fat in meals [3,50]. Here, a decreased circulating level of 8-iso-PGF$_2\alpha$ was highlighted, a feature negatively correlated with the visceral fat ratio and android fat across the 40 subjects and positively with blood pressure. Others have characterized how increased blood and urinary levels of 8-iso-PGF$_2\alpha$ correlate with oxidative stress and android obesity [3,51]. 8-iso-PGF$_2\alpha$ is generally released from the site of inflammation as esters of phospholipid (bound) or through the action of phospholipase A2 in free form [52]. 8-iso-PGF$_2\alpha$ concentration was positively correlated with the concentrations of several ether lipids decreasing with visceral adiposity (e.g. PC-O 40:4, PC-O 42:2, PC-O 42:3, PC-O 42:4). Furthermore, whilst 12- and 15-LO enzymes are known to be up-regulated in visceral adipocytes, their products (12- and 15-hydroxy-eicosatetraenoic acid 12/15-HETE) promote proinflammatory state and impairing insulin signaling in adipocytes [4,53]. However, the circulating levels of 12/15-HETE concentrations were not statistically different between groups, suggesting that the circulating levels of these molecules in fasting blood are not directly related to visceral fat metabolism under the current experimental conditions.

Figure 5. Spearman correlation network between blood plasma metabolic markers highlighting strong functional relationships between phospholipids and eicosanoid metabolic remodelling. Non significant correlations and those between 0.4 and $-0.4$ were removed to reduce the number of edges and facilitate visualization.
doi:10.1371/journal.pone.0073445.g005

Visceral Adiposity Links to a Specific Amino Acid Pattern Associated with Deregulated Insulin Signaling

Plasma amino acids (including glutamine, leucine/isoleucine, phenylalanine and tyrosine) significantly contributed to the metabolic phenotypes of visceral adiposity, with a greater specificity being observed for glutamine and tyrosine levels. Our findings are partly supported by a recent report on obese Japanese subjects in which plasma levels of alanine, glycine, glutamate, tryptophan, tyrosine and BCAA amino acids associated with visceral fat accumulation [27]. Our results support associations of levels of BCAA and tyrosine with visceral adiposity, irrespective of ethnicity, lifestyle and environmental conditions. Although requiring proper validation on a larger population, one may postulate that levels of glycine, glutamate, tryptophan, glutamine and phenylalanine associated with visceral adiposity could be genetic and environmental dependent either in healthy obese [27] or in pre-diabetic subjects as recently reported [54]. Association of BCAA levels with visceral adiposity is supported by previous reports proposing these as co-variants of insulin resistance [55,56]. In fact, BCAA catabolism is tightly intertwined with insulin resistance, and greater circulating levels of BCAA were reported under these conditions [57,58]. In particular, a combination of three amino acids (isoleucine, phenylalanine, tyrosine) could predict future diabetes (>5-fold higher risk for individuals in top quartile) [59,60]. Recent results showed that fat tissue metabolism is key in determining the blood level of branch chain amino acids [61]. Indeed, it is suggested that altered signaling in white adipose tissue under insulin resistance, pre-diabetes or type 2 diabetes
conditions can induce decreased expression of branched-chain-keto acid dehydrogenase (BCKD) with inferred impairment of BCAA utilization as metabolic fuel in this tissue. As a result, one may postulate that this reduced BCAA utilization in adipose tissue increases the circulating pool of isoleucine and its direct catabolic product, the 3-methyl-2-oxovaleric acid, via reversible transamination by branched chain amino-acid transaminase 1. This may explain the observed increased urinary excretion of 3-methyl-2-oxovaleric acid in high visceral fat subjects. In the present study, visceral adiposity was associated with different response to OGTT, as noted with an early increase in post-glucose insulin concentrations and enhanced glucose-induced insulin secretion. Knowing that insulin resistance is a causal mechanism in the etiology of visceral fat development and related disorders, the observation of such amino acid and OGTT patterns support this functional relationship. Moreover, removal of intraperitoneal fat tissue, a major compartment of visceral adiposity, significantly restores glucose and insulin towards normal levels in humans, but not subcutaneous adipose tissue [22].

The study presents several potentialities, including the use of CT and DXA measurements to provide robust biological readouts to compare the association between different estimates of visceral adiposity. Then, the subjects were recruited from a well-defined population, which represented a single ethnic group under well-defined conditions and healthy medical criteria. This study also has several limitations, due to exploratory nature and the use of a single cohort study with a small number of subjects and the results are confined to this specific cohort. Therefore, further studies are needed to determine the predictive role of the highlighted metabolic signature clustering of cardiometabolic risk factors and subsequent incidence of cardiovascular diseases. Since the metabolic signatures encompass features related to glucose/insulin metabolism, future studies should investigate closely the relationships between metabolism, visceral adiposity and glucose tolerance classes. Moreover, there is compelling evidence that relationships between abdominal fat distribution and insulin and non-insulin-mediated glucose uptake in females are dependent on endogenous androgens [62], whilst the global adiposity and thickness of intraperitoneal and mesenteric adipose tissue depots have been found increased in women with polycystic ovary syndrome [63]. It will be therefore key in future studies to comprehensively integrate endocrinopathy with metabolic and other physiological parameters.

Conclusions

The integration of visceral fat estimates with metabolic profiles of blood and urine described a distinct amino acid, diacetyl and ether phospholipid phenotype associated with higher visceral fat in a healthy obese women cohort. Metabolic importance and robustness in predicting visceral fat adiposity as assessed by Random forest analysis highlighted 7 most robust markers, including tyrosine, glutamine, PC-0 44:6, PC-0 44:4, PC-0 42:4, PC-0 40:4, and PC-0 40:3. Moreover, the inflammatory intermediate profile appears of lower relevance for clinical assessment of visceral fat due to greater inter-days and between-subject variations. Considering the recent studies regarding at metabolic processes associated with different body fat distributions, it becomes imperative that the following studies comprehensively report anthropometric, endocrine, clinical and medical details of the cohort, in addition to race/ethnic and age variability. This will allow a stronger link to unravel metabolic susceptibilities to metabolic syndrome and cardiovascular health. Such reports will enable proper comparison of metabolic findings and follow-up in larger populations. In future, systemic metabolomic visceral adiposity biomarkers might also be extended to distinguish its mesenteric, epicardial and peripheral deposition subtypes which may link even more specifically to cardiometabolic status of patients with disorders or at risk of diseases.

Supporting Information

Figure S1 Loadings plot from Principal component analysis of CT and DEXA body composition parameters. First two principal components explained 42 and 17% of the total variance.

(TIF)

Figure S2 Loadings plot from orthogonal partial least square analysis of Log10 value of ratio 1 with CT and DEXA body composition parameters. OPLS model was generated with 1 predictive and 2 orthogonal components (R2X = 0.60, R2Y = 0.96, Q2Y = 0.90).

(TIF)

Figure S3 Loadings plot from Principal component analysis of CT, DEXA body composition and clinical parameters. First two principal components explained 29 and 13% of the total variance.

(TIF)

Figure S4 Loadings plot from orthogonal partial least square analysis of Log10 value of ratio 1 with CT and DEXA body composition parameters. OPLS model was generated with 1 predictive and 2 orthogonal components (R2X = 0.45, R2Y = 0.92, Q2Y = 0.75).

(TIF)

Figure S5 Linear regression between glucose response to OGTT and visceral adiposity.

(TIF)

Figure S6 Statistical reconstruction of 1H NMR blood plasma profiles using random forest analysis to identify metabolic patterns associated with visceral adiposity (as identified with squared boxes). GPCs = glycerophospholipids, PUFAs = polyunsaturated fatty acids, UFAs = unsaturated fatty acids.

(TIF)

Figure S7 Scheme summarizing metabolic differences in the arachidonic and linoleic acid metabolic pathway across the four groups of visceral adiposity (Q1, Q2, Q3, and Q4). Bar plots describing metabolite variations in the study population stratified in four quartiles according to visceral fat adiposity (intraperitoneal). Statistical significance is reported in Table S2. Key: QE data for population quartile i according to intraperitoneal/abdominal fat ratio. 12-HETE, 12-hydroxy-eicosatetraenoic acid; 15-HETE, 15-hydroxy-eicosatetraenoic acid; 9-HODE, 9-Hydroxy-10,12-octadecadienoic acid; AA, arachidonic acid.

(TIF)

Figure S8 Statistically significant Spearman correlation map between visceral fat parameters CT scan, DXA data and main clinical parameters (95% confidence interval). HOMA-IR is negatively correlated with PC-0 42:4, PC-0 44:4, and PC-0 44:6 lipid species, and positively with blood triglycerides, γGT, and age. ALAT/ASAT ratio showed positive correlation with AA and EPA, PC 34:4, PC 30:0 and LPC 24:0 lipid species, but also fasting blood insulin, γGT and triglycerides, waist circumference and waist to hip ratio. Blue denotes negative
correlation, orange denotes positive correlation, and black denotes no correlation.

Text S1 Sample Preparation and 1H-NMR Spectroscopic Analysis.

Table S1 Descriptive statistics of subjects stratified according to intraperitoneal fat volume.

Table S2 Descriptive statistics of subjects stratified according to intraperitoneal/subcutaneous fat ratio.

Table S3 Metabolite variations across of subjects stratified according to intraperitoneal fat volume.

Table S4 Metabolic variations across subjects stratified according to intraperitoneal/subcutaneous fat ratio.

Table S5 Metabolite VIP ranking based on PLS models generated at V2+V0.

Text S1 Sample Preparation and 1H-NMR Spectroscopic Analysis.

References

1. Lasere AM, Chiodero A, Paccaud F, Bovet P (2007) Worldwide trends in childhood obesity. Swiss Med Wkly 137: 157–158.
2. Chiodero A, Lasere AM, Paccaud F, Bovet P (2007) [Childhood obesity: definition, consequences, and prevalence]. Rev Med Suisse 3: 1262–1269.
3. Davi G, Gaugnano MT, Ciafardt G, Basili Silvano A, et al. (2002) Platelet activation in obese women: role of inflammation and oxidant stress. JAMA 288: 2008–2014.
4. Chakrabarti SK, Cole BK, Wen Y, Keller SR, Nadler JL, et al. (2008) 12/15-lipoxygenase products induce inflammation and impair insulin signaling in ST3-L1 adipocytes. Obesity (Silver Spring) 16: 1567–1603.
5. Donahue RP, Abbott RD (1987) Central obesity and coronary heart disease in men. Lancet 2: 1215.
6. Lapalus L, Bengtsson G, Larsson B, Pennert K, Rybo E, et al. (1984) Distribution of adipose tissue and risk of cardiovascular disease and death: a 12-year follow up of participants in the population study in women in Gothenburg, Sweden. Br Med J (Clin Res Ed) 289: 1257–1261.
7. Kalkhoff RR, Hurtz AH, Rupley D, Kisselbath AH, Kelber S (1983) Relationship of body fat distribution to blood pressure, carbohydrate tolerance, and plasma lipids in healthy obese women. J Clin Med 102: 621–627.
8. Despres JP, Tremblay A, Lefebvre C, Bouchard C (1988) Effect of the amount of body fat on the age-associated increase in serum cholesterol. Prev Med 17: 423–431.
9. Park SH, Kim BI, Kim SH, Kim HJ, Park DJ, et al. (2007) Body fat distribution and insulin resistance: beyond obesity in nonalcoholic fatty liver disease among overweight men. J Am Coll Nutr 26: 321–326.
10. Folsom AR, Kaye SA, Sellers TA, Hong CP, Cerhan JR, et al. (1993) Body fat distribution and 5-year risk of death in older women. JAMA 269: 483–487.
11. Samaras K, Kelly PJ, Chiano MN, Spector TD, Campbell LV (1999) Genetic and environmental influences on total-body and central abdominal fat: the effect of physical activity in female twins. Ann Intern Med 130: 873–882.
12. Batra A, Siegmund B (2012) The role of visceral fat. Dig Dis 30: 70–74.
13. Viguerie N, Vidal H, Arner P, Holst C, Verdich C, et al. (2005) Adipose tissue composition in Nonobese Adults. J Clin Densitom.
14. Sorensen TI, Boutin P, Taylor MA, Larsen LH, Verdich C, et al. (2006) Genetic polymorphisms and weight loss in obesity: a randomised trial of hypo-energetic high- versus low-fat diets. PLoS Clin Trials 1: e12.
15. Klaassen M, Orlo M, Langin D, Laurell H, Holm C, et al. (1998) The putative role of the hormone-sensitive lipase gene in the pathogenesis of Type II diabetes mellitus and abdominal obesity. Diabetologia 41: 1516–1522.
16. Fox CS, Liu Y, White CC, Feiiosa M, Smith AV, et al. (2012) Genome-wide association for abdominal subcutaneous and visceral adipose reveals a novel locus for visceral fat in women. PLoS Genet 8: e1002695.
17. Toran-Garcia M, Bouchard C (2007) Genetics of the metabolic syndrome. Appl Physiol Nutr Metab 32: 89–114.
18. Levy R, Turnbaugh P, Klein S, Gordon J (2006) Microbial ecology: human gut microbes associated with obesity. Nature 444: 1022–1023.
19. Wildman RP, Muntner P, Reynolds K, McGinn AP, Rajagath S, et al. (2008) The obese without cardiometabolic risk factor clustering and the normal weight with cardiometabolic risk factor clustering: prevalence and correlates of 2 phenotypes among the US population [NHAES 1999–2004]. Arch Intern Med 168: 1617–1624.
20. Snith SC, Jr., Haslam D (2007) Abdominal obesity, waist circumference and cardiometabolic risk: awareness among primary care physicians, the general population and patients at risk—the Shape of the Nations survey. Curr Med Res Opin 23: 29–47.
21. Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, et al. (2004) Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 364: 937–952.
22. Dullaio AG, Montani JP (2010) Phenotyping for early predictors of obesity and the metabolic syndrome. Int J Obes (Lond) 34 Suppl 2: S1–S3.
23. Nicholson JK, Holmes E, Wilson ID (2005) Gut microorganisms, mammalian metabolism and personalized health care. Nat Rev Microbiol 3: 431–438.
24. Li M, Wang B, Zhang M, Rantalainen M, Wang S, et al. (2008) Symbiotic gut microbes modulate human metabolic phenotypes. Proc Natl Acad Sci U S A 105: 1117–2122.
25. Martin FJ, Wang Y, Sprenger N, Yap IKS, Rezzi S, et al. (2008) Top-down Systems Biology Integration of Conditional Prebiotic Transgenic Interactions in a Humanized Microbiome Mouse Model. Mol Syst Biol 4: 205.
26. Saymaniska E, Bouwman J, Strassburg K, Vervoort J, Kangas AJ, et al. (2012) Gender-dependent associations of metabolite profiles and body fat distribution in a healthy population with central obesity: towards metabolomics diagnostics. OMICS 16: 652–667.
27. Yamakado M, Tanaka T, Nagao K, Ishizaka Y, Mitushima T, et al. (2012) Plasma amino acid profile is associated with visceral fat accumulation in obese Japanese subjects. Clinical Obesity 2: 29–40.
28. Rothney MP, Martin FP, Xia Y, Beaumont M, Davis C, et al. (2012) Precision of GE. Lunar iDXA for the Measurement of Total and Regional Body Composition in Nonobese Adults. J Clin Densitom.
29. Kashi BM, Pedley A, Massaro JM, Murabito J, Hoffmann U, et al. (2012) The ratio of visceral to subcutaneous fat, a metric of body fat distribution, is a unique correlate of cardiometabolic risk. Diabetologia 55: 2622–2630.
30. Baur P, Martin FP, Gruber I, Bosco N, Brahmbhatt V, et al. (2011) Metabolic phenotyping of the Crohn's Disease-like IBD Etiopathology in the TNPBel-taARE/WT Mouse Model. J Proteome Res 10: 5524–5535.
31. Wold S, Esbensen K, Geladi P (1986) Principal Component Analysis. Chemom Intell Lab Syst 2: 37–52.
32. Wold S, Esbensen K, Geladi P (1987) Omics Systems Biology Integration of Conditional Prebiotic Transgenic Interactions in a Humanized Microbiome Mouse Model. Mol Syst Biol 4: 205.
33. Trygg J, Wold S (2003) O2-PLS, a two-block (X-Y) latent variable regression method with an integrated OSC filter. J Chemom 17: 53–64.
34. Baur P, Martin FP, Gruber I, Bosco N, Brahmbhatt V, et al. (2011) Metabolic phenotyping of the Crohn's Disease-like IBD Etiopathology in the TNPBel-taARE/WT Mouse Model. J Proteome Res 10: 5524–5535.
35. Liaw A, Wiener M (2002) Classification and regression by randomForest. R News 3: 18–22.
36. Martin FP, Wrote the paper: FPJM IM SC MS MPR DLE FG MB SDQ. Contributed reagents/experiments: FPJM SC PG IT AT MB SDQ LF VG. Analyzed the data: FPJM IM SC MS MPR DLE FG MB SDQ. Contributed reagents/materials/analysis tools: FPJM SC MS PG IT AT SM MB MPR DLE. Wrote the paper: FPJM IM SC MS MB VG SR.

Text S2 Sample preparation for Biocrates Life Sciences AbsoluteIDQ™ kit analysis.

Text S3 Sample preparation and inflammation marker quantification by UPLC-ESI-MS/MS using isotope dilution technique.

Acknowledgments

We thank the CHUV and S. Oguey-Araymon, A. Blondel Labranzo and C. Nielsen Moennoz at the Metabolic Unit of the Nestlé Research Center for the study design and all sample provision. We thank Dr. Viral Brahmbhatt and Dr. Alastair Ross (Nestlé Research Center) for their scientific input during the conduction of the study and data analysis.

Author Contributions

Conceived and designed the experiments: FPJM SR VG. Performed the experiments: FPJM SC PG IT AT MB SDQ LF VG. Analyzed the data: FPJM IM SC MS MPR DLE FG MB SDQ. Contributed reagents/materials/analysis tools: FPJM SC MS PG IT AT SM MB MPR DLE. Wrote the paper: FPJM IM SC MS MB VG SR.
36. Lee MJ, Wu Y, Fried SK (2013) Adipose tissue heterogeneity: implication of depot differences in adipose tissue for obesity complications. Mol Aspects Med 34: 1–11.
37. Kang SM, Yoon JW, Ahn HY, Kim SY, Lee KH, et al. (2011) Android fat depot is more closely associated with metabolic syndrome than abdominal visceral fat in elderly people. PLoS ONE 6: e27694.
38. Zoeller RA, Lake AC, Nagan N, Gaposchkin DP, Legner MA, et al. (1999) Plasmalogens as endogenous antioxidants: somatic cell mutants reveal the importance of the vinyl ether. Biochem J 339 (Pt 3): 769–776.
39. Wallner S, Schmitz G (2011) Plasmalogens: the neglected regulatory and scavenging lipid species. Chem Phys Lipids 164: 573–589.
40. Pietilainen KH, Sysi-Aho M, Rissanen A, Seppanen-Laakso T, Yki-Jarvinen H, et al. (2007) Abdominal obesity is associated with changes in the serum lipidomic profile independent of genetic effects—a monozygotic twin study. PLoS ONE 2: e218.
41. Schrakamp G, Schutgens RB, Wanders RJ, Heymans HS, Tager JM, et al. (1985) The cerebro-hepato-renal (Zellweger) syndrome. Impaired de novo biosynthesis of plasmalogens in cultured skin fibroblasts. Biochim Biophys Acta 833: 170–174.
42. Marba R, Maeda T, Kinoshita M, Takao K, Takenaka H, et al. (2007) Plasmalogens in human serum positively correlate with high-density lipoprotein and decrease with aging. J Atheroscler Thromb 14: 12–18.
43. Okazaki M, Usui S, Ishigami M, Sakai N, Nakamura T, et al. (2005) Identification of unique lipoprotein subclasses for visceral obesity by component analysis of cholesterol profile in high-performance liquid chromatography. Arterioscler Thromb Vasc Biol 25: 578–584.
44. Lemieux S, Despres JP, Moorjani S, Theriault G, et al. (1994) Are gender differences in cardiovascular disease risk factors explained by the level of visceral adipose tissue? Diabetologia 37: 757–764.
45. Hoegel A, Stefan N, Yu Z, Mühlenbruch K, Drogan D, et al. (2012) Identification of Serum Metabolites Associated With Risk of Type 2 Diabetes Using a Targeted Metabolomic Approach. Diabetes 62: 639–648.
46. Snyder F (1995) Platelet-activating factor and its analogs: metabolic pathways and related intracellular processes. Biochim Biophys Acta 1254: 231–249.
47. McIntyre TM, Prescott SM, Stadilomi DM (2009) The emerging roles of PAF acetylhydrolase. J Lipid Res 50 Suppl: S253–S259.
48. Basili S, Pacini G, Guagnano MT, Manigrasso MR, Santilli F, et al. (2006) Insulin resistance as a determinant of platelet activation in obese women. J Am Coll Cardiol 48: 2531–2538.
49. Wu B, Fukuo K, Suzuki K, Yoshino G, Kazumi T (2009) Relationships of systemic oxidative stress to body fat distribution, adipokines and inflammatory markers in healthy middle-aged women. Endocr J 56: 773–782.
50. Pears AD, Rankin JV, Lee YW (2011) Effects of acute ingestion of different fats on oxidative stress and inflammation in overweight and obese adults. Nutr J 10: 122.
51. Szuldrzynski K, Zalewski J, Machnik A, Zmudka K (2010) Elevated levels of β-isoprostaglandin F2α in acute coronary syndromes are associated with systemic and local platelet activation. Pol Arch Med Wewn 120: 19–24.
52. Leitinger N, Blazek I, Sinzinger H (1997) The influence of isoprostanes on ADP-induced platelet aggregation and cyclic AMP generation in human platelets. Thromb Res 86: 337–342.
53. Chakrabarti SK, Sen Y, Dobrian AD, Cole BK, Ma Q, et al. (2011) Evidence for activation of inflammatory lipoygenase pathways in visceral adipose tissue of obese Zucker rats. Am J Physiol Endocrinol Metab 300: E173–E187.
54. Wang-Sattler R, Yu Z, Herder C, Messiaen AC, Floegel A, et al. (2012) Novel biomarkers for pre-diabetes identified by metabolomics. Mol Syst Biol 8: 615.
55. Newgard CB, An J, Bain JR, Muehlbauer MJ, Stevens RD, et al. (2009) A branched-chain amino acid-related metabolic signature that differentiates obese and lean humans and contributes to insulin resistance. Cell Metab 9: 311–320.
56. Suhre K, Mifsud C, Doring A, Altmaier E, Belcredi P, et al. (2010) Metabolic footprint of diabetes: a multiplatform metabolomics study in an epidemiological setting. PLoS ONE 5: e10953.
57. Huffman KM, Shah SH, Stevens RD, Bain JR, Muehlbauer M, et al. (2009) Relationships between circulating metabolic intermediates and insulin action in overweight to obese, inactive men and women. Diabetes Care 32: 1678–1683.
58. Fiolo O, Garvey WT, Newman JW, Lok KH, Hoppel CL, et al. (2010) Plasma metabolomic profiles reflective of glucose homeostasis in non-diabetic and type 2 diabetic obese African-American women. PLoS ONE 5: e15234.
59. Rhee EP, Cheng S, Larson MG, Walford GA, Lewis GD, et al. (2011) Lipid profiling identifies a triacylglycerol signature of insulin resistance and improves diabetes prediction in humans. J Clin Invest 121: 1402–1411.
60. Wang TJ, Larson MG, Vasan RS, Cheng S, Rhee EP, et al. (2011) Metabolite profiles and the risk of developing diabetes. Nat Med 17: 448–453.
61. Lackey DE, Lynch CJ, Olsson KG, Mostadk R, Ali M, et al. (2013) Regulation of adipose branched chain amino acid catabolism enzyme expression and cross-adipose amino acid flux in human obesity. American Journal of Physiology - Endocrinology And Metabolism 304: E1175–87.
62. Euch U, Pall M, Mathur R, Dey D, Berman D, et al. (2013) Effects of endogenous androgens and abdominal fat distribution on the interrelationship between insulin and non-insulin-mediated glucose uptake in females. J Clin Endocrinol Metab 98: 1541–1548.
63. Borrueil S, Fernandez Duran E, Alpamay M, Marit D, Alvarez-Blasco F, et al. (2013) Global adiposity and thickness of interperitoneal and mesenteric adipose tissue depots are increased in women with polycystic ovary syndrome (PCOS). J Clin Endocrinol Metab 98: 1254–1263.